Acute ischemic coronary artery disease and ischemic stroke: Similarities and differences

American Journal of Therapeutics

Volumn 15, Issue 2, 2008, Pages 137-149

  Fisher, Marc ^a,b   Folland, Edward ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b University of Massachusetts   (United States)

Author keywords

Myocardial infarction; Stroke; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DESMOTEPLASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DISUFENTON SODIUM; FIBRINOLYTIC AGENT; GLYCOPROTEIN 2B INHIBITOR; GLYCOPROTEIN 3A INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROUROKINASE; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADD ON THERAPY; ARTERY EMBOLISM; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG INHIBITION; DRUG POTENTIATION; ELECTROCARDIOGRAM; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; MONOTHERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; STROKE;

EID: 41549144952     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31816a61bb     Document Type: Review

References (78)

1. American Heart Association. Heart Disease and Stroke Statistics - 2006 Update. Dallas: American Heart Association, 2006.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue PA for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
3. Yeghiazarians Y, Braunstein JB, Askari A, et al. Unstable angina pectoris. N Engl J Med. 2000;342:101-114.
4. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985;5:609-616.
5. Peterson ED, Shaw LD, Califf RM. Risk stratification after myocardial infarction. Ann Intern Med. 1997;126:561.
6. Gibson CM. Time is myocardium and time is outcomes. Circulation. 2001;104:2632.
7. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction, executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) [Erratum in: J Am Coll Cardiol. 2005;45:1376]. J Am Coll Cardiol. 2004;44:671-719.
8. Hamm CW, Braunwald E. A classification of unstable angina-revisited. Circulation. 2000;102:118.
9. Wolf PA. Epidemiology of stroke. In: Mohr JP, Choi DW, Grotta JC, et al, eds. Stroke: Pathophysiology, Diagnosis, and Management, ed 4. Philadelphia: Churchill Livingstone, 2004:13-34.
10. Fisher M, Paganini-Hill A, Martin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis. Stroke. 2005;36:253-257.
11. Ogata J, Masuda J, Yutani C, et al. Mechanisms of cerebral artery thrombosis: a histopathological analysis on eight necropsy cases. J Neurol Neurosurg Psychiatry. 1994;57:17-21.
12. Garcia JH, Ho KL. Pathology of hypertensive arteriopathy. Neurosurg Clin North Am. 1992;3:497-507.
13. Fisher CM. Capsular infarcts: the underlying vascular lesions. Arch Neurol. 1979;36:65-73.
14. Luijckx GJ, Boiten J, Lodder J, et al. Cardiac and carotid embolism, and other rare definite disorders are unlikely causes of lacunar ischemic stroke in young patients. Cerebrovasc Dis. 1996;6:28-31.
15. Woolfden AR, Albers GW. Cardioembolic stroke. In: Fisher M, Bogousslavsky J, eds. Current Review of Cerebrovascular Disease, ed 4. Philadelphia: Current Medicine, 2001:123-136.
16. Onal MZ, Fisher M, Bogousslavsky J. Clinical evaluation of stroke. In: Fisher M, Bogousslavsky J, eds. Current Review of Cerebrovascular Disease, ed 4. Philadelphia: Current Medicine, 2001:102-114.
17. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
18. Kidwell CS, Chalela J, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA. 2004;292:1823-l830.
19. von Kummer R, Allen KL, Helle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. 1997;205:327-333.
20. Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001;286:2830-2838.
21. Shen Q, Ren H, Cheng H, et al. Functional, perfusion and diffusion MRI of acute focal ischemic brain injury. J Cereb Blood Flow Metab. 2005;25:1265-1279.
22. Meng X, Fisher M, Shen Q, et al. Characterizing the diffusion/perfusion mismatch in a rat stroke model of focal cerebral ischemia. Ann Neurol. 2004;55:207-212.
23. Fisher M. Characterizing the target of acute stroke treatment. Stroke. 1997;28:866-872.
24. Schellinger PD, Fieback JB, Jansen O, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol. 2001;49:460-469.
25. Wintermark M, Bogousslavsky J, Thiren JP, et al. Prognostic accuracy of admission cerebral blood flow measurements by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol. 2002;51:417-432.
26. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke. 2005;36:602-606.
27. Thomalla G, Schwark C, Sobesky J, et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke. 2006;37:852-858.
28. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients [Erratum in: Lancet. 1994;343:742]. Lancet. 1994;343:311-322.
29. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
30. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-75.
31. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
32. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N EngI J Med. 1993;329:673-682.
33. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716-722.
34. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771-775.
35. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
36. The TEMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction, Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989;320:618-627.
37. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.
38. Thrombolysis in Myocardial Ischemia Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Circulation. 1994;89:1545-1556.
39. Baigent C, Collins R, Appleby P, et al. 1SIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316:1337-1343.
40. Franzosi MG, Santoro B, De Vita C, et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-l study. The GISSI investigators. Circulation. 1998;98:2659-2665.
41. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993;328:673-679.
42. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328:680-684.
43. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med. 1993;328:685-691.
44. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733-742.
45. The TIM1 Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. JAMA. 1988;260:2849-2858.
46. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
47. Simoons MI, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet. 1988;1:197-203.
48. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624-629.
49. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
50. Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708-715.
51. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ilb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
52. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172:1307-1312.
53. Katzan IL, Hammer MD, Furlan AJ, et al. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Cleveland Clinic Health System Stroke Quality Improvement Team. Stroke. 2003;34:799-800.
54. Bravata DM, Kim N, Concato J, et al. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med. 2002;62:1994-2001.
55. Hacke W, Albers GW, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. DIAS Study Group. Stroke. 2005;36:66-73.
56. Hacke W, for the DIAS and DEDAS Steering Committees and Investigators. The results of the joint analysis of two phase II trials of desmoteplase in acute ischemic stroke with treatment 3 to 9 hours after stroke onset. Presented at the 14th European Stroke Conference, May 28, 2005, Bologna, Italy.
57. Furlan A, Higashida R, Wechsler LA, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
58. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke. 2004;35:904-911.
59. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx. 2004;1:46-70.
60. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
61. National Cholesterol Education Program. Third report of the Expert Panel on Detection, Evaluation, and Treatment of Right Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, Sept. 2002, ppl-284. NIH publication 02-5125. Available at: http://www.nhlbi.hih.gov/guidelines/cholesterol/. Accessed April 11, 2006.
62. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes [Erratum in: N Engl J Med. 2006;354:778]. N Engl J Med. 2004;350:1495-1504.
63. The SPARCL Investigators. The Stroke Prevention by Aggressive Reduction Levels (SPARCL) Study. Presented at the 15th European Stroke Conference, May 2006, Brussels, Belgium.
64. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals. Lancet. 2002;360:7-22.
65. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [Erratum in: BMJ. 2002;324:141]. BMJ. 2002;324:71-86.
66. Nurden AT. Platelet function and pharmacology of antiplatelet drugs. Cerebrovasc Dis. 1997;7:2-9.
67. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345:669-685.
68. Strauss SE, Majaumdar SR, McAllister FA. New evidence for stroke prevention. JAMA. 2002;288:1388-1395.
69. Sacco RL, Adams R, Albers GW, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Co-sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Stroke. 2006;37:577-617.
70. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [Erratum in: Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
71. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
72. CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE). Lancet. 1996;348:1329-1339.
73. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators [Errata in: N Engl J Med. 2001;345:1716; N Engl J Med. 2001;345:1506]. N Engl J Med. 2001;345:494-502.
74. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
75. Diener HC, Bougousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. MATCH Investigators. Lancet. 2004;364:331-337.
76. Fisher M. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for neurologists. Arch Neurol. 2006;63:20-24.
77. Diener H-C, Cunha L, Forbes C, et al. European Stroke Prevention Study. Part II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
78. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367:1665-1674.